Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice

Psychopharmacology (Berl). 2008 Dec;201(2):203-18. doi: 10.1007/s00213-008-1268-7. Epub 2008 Aug 19.

Abstract

Rationale: Serotonin transporter (SERT) knockout (-/-) mice have an altered phenotype in adulthood, including high baseline anxiety and depressive-like behaviors, associated with increased baseline extracellular serotonin levels throughout life.

Objectives: To examine the effects of increases in serotonin following the administration of the serotonin precursor 5-hydroxy-L-tryptophan (5-HTP) in SERT wild-type (+/+), heterozygous (+/-), and -/- mice.

Results: 5-HTP increased serotonin in all five brain areas examined with approximately 2- to 5-fold increases in SERT+/+ and +/- mice, and with greater 4.5- to 11.7-fold increases in SERT-/- mice. Behaviorally, 5-HTP induced exaggerated serotonin syndrome behaviors in SERT-/-, mice with similar effects in male and female mice. Studies suggest promiscuous serotonin uptake by the dopamine transporter (DAT) in SERT-/- mice, and here, the DAT blocker GBR 12909 enhanced 5-HTP-induced behaviors in SERT-/- mice. Physiologically, 5-HTP induced exaggerated temperature effects in SERT-deficient mice. The 5-HT1A antagonist WAY 100635 decreased 5-HTP-induced hypothermia in SERT+/+ and +/- mice with no effect in SERT-/- mice, whereas the 5-HT7 antagonist SB 269970 decreased this exaggerated response in SERT-/- mice only. WAY 100635 and SB 269970 together completely blocked 5-HTP-induced hypothermia in SERT+/- and -/- mice.

Conclusions: These studies demonstrate that SERT-/- mice have exaggerated neurochemical, behavioral, and physiological responses to further increases in serotonin, and provide the first evidence of intact 5-HT7 receptor function in SERT-/- mice, with interesting interactions between 5-HT1A and 5-HT7 receptors. As roles for 5-HT7 receptors in anxiety and depression were recently established, the current findings have implications for understanding the high anxiety and depressive-like phenotype of SERT-deficient mice.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • 5-Hydroxytryptophan / pharmacology
  • 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology
  • Animals
  • Brain / anatomy & histology
  • Brain / drug effects
  • Brain / metabolism
  • Brain Chemistry / drug effects*
  • Catecholamines / antagonists & inhibitors
  • Catecholamines / classification
  • Clorgyline / pharmacology
  • Dopamine Uptake Inhibitors / pharmacology
  • Drug Synergism
  • Drug Therapy, Combination
  • Female
  • Hydroxyindoleacetic Acid / analysis
  • Hydroxyindoleacetic Acid / metabolism
  • Hypothermia / chemically induced
  • Male
  • Mice
  • Mice, Knockout
  • Monoamine Oxidase Inhibitors / pharmacology
  • Phenols / pharmacology
  • Piperazines / pharmacology
  • Piperazines / toxicity
  • Pyridines / pharmacology
  • Serotonin / analogs & derivatives
  • Serotonin / metabolism*
  • Serotonin / pharmacology
  • Serotonin 5-HT1 Receptor Antagonists
  • Serotonin Plasma Membrane Transport Proteins / deficiency*
  • Serotonin Plasma Membrane Transport Proteins / genetics
  • Serotonin Receptor Agonists / pharmacology
  • Serotonin Syndrome / chemically induced
  • Sulfonamides / pharmacology
  • Tranylcypromine / pharmacology

Substances

  • Catecholamines
  • Dopamine Uptake Inhibitors
  • Monoamine Oxidase Inhibitors
  • Phenols
  • Piperazines
  • Pyridines
  • SB 269970
  • Serotonin 5-HT1 Receptor Antagonists
  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin Receptor Agonists
  • Sulfonamides
  • Serotonin
  • Tranylcypromine
  • Hydroxyindoleacetic Acid
  • N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide
  • 8-Hydroxy-2-(di-n-propylamino)tetralin
  • vanoxerine
  • 5-carboxamidotryptamine
  • 5-Hydroxytryptophan
  • Clorgyline